Guy Christopher L, Weiss Elisabeth, Jan Nuzhat, Reshko Leonid B, Christensen Gary E, Hugo Geoffrey D
Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia 23298.
Department of Electrical and Computer Engineering and Department of Radiation Oncology, University of Iowa, Iowa City, Iowa 52242.
Med Phys. 2016 Nov;43(11):6109. doi: 10.1118/1.4965807.
To characterize mass and density changes of lung parenchyma in non-small cell lung cancer (NSCLC) patients following midtreatment resolution of atelectasis and to quantify the impact this large geometric change has on normal tissue dose.
Baseline and midtreatment CT images and contours were obtained for 18 NSCLC patients with atelectasis. Patients were classified based on atelectasis volume reduction between the two scans as having either full, partial, or no resolution. Relative mass and density changes from baseline to midtreatment were calculated based on voxel intensity and volume for each lung lobe. Patients also had clinical treatment plans available which were used to assess changes in normal tissue dose constraints from baseline to midtreatment. The midtreatment image was rigidly aligned with the baseline scan in two ways: (1) bony anatomy and (2) carina. Treatment parameters (beam apertures, weights, angles, monitor units, etc.) were transferred to each image. Then, dose was recalculated. Typical IMRT dose constraints were evaluated on all images, and the changes from baseline to each midtreatment image were investigated.
Atelectatic lobes experienced mean (stdev) mass changes of -2.8% (36.6%), -24.4% (33.0%), and -9.2% (17.5%) and density changes of -66.0% (6.4%), -25.6% (13.6%), and -17.0% (21.1%) for full, partial, and no resolution, respectively. Means (stdev) of dose changes to spinal cord D, esophagus D, and lungs D were 0.67 (2.99), 0.99 (2.69), and 0.50 Gy (2.05 Gy), respectively, for bone alignment and 0.14 (1.80), 0.77 (2.95), and 0.06 Gy (1.71 Gy) for carina alignment. Dose increases with bone alignment up to 10.93, 7.92, and 5.69 Gy were found for maximum spinal cord, mean esophagus, and mean lung doses, respectively, with carina alignment yielding similar values. 44% and 22% of patients had at least one metric change by at least 5 Gy (dose metrics) or 5% (volume metrics) for bone and carina alignments, respectively. Investigation of GTV coverage showed mean (stdev) changes in V, D, and D of -5.5% (13.5%), 2.5% (4.2%), and 0.8% (8.9%), respectively, for bone alignment with similar results for carina alignment.
Resolution of atelectasis caused mass and density decreases, on average, and introduced substantial changes in normal tissue dose metrics in a subset of the patient cohort.
描述非小细胞肺癌(NSCLC)患者在治疗中期肺不张消退后肺实质的质量和密度变化,并量化这种大的几何形状变化对正常组织剂量的影响。
获取了18例伴有肺不张的NSCLC患者的基线和治疗中期CT图像及轮廓。根据两次扫描之间肺不张体积的减少情况,将患者分为完全消退、部分消退或未消退。基于每个肺叶的体素强度和体积,计算从基线到治疗中期的相对质量和密度变化。患者还拥有临床治疗计划,用于评估从基线到治疗中期正常组织剂量限制的变化。治疗中期图像通过两种方式与基线扫描进行刚性配准:(1)骨骼解剖结构;(2)隆突。将治疗参数(射野孔径、权重、角度、监测单位等)转移到每个图像上。然后,重新计算剂量。在所有图像上评估典型的调强放疗剂量限制,并研究从基线到每个治疗中期图像的变化。
对于完全消退、部分消退和未消退的情况,肺不张肺叶的平均(标准差)质量变化分别为-2.8%(36.6%)、-24.4%(33.0%)和-9.2%(17.5%),密度变化分别为-66.0%(6.4%)、-25.6%(13.6%)和-17.0%(21.1%)。对于骨骼配准,脊髓D、食管D和肺D的剂量变化均值(标准差)分别为0.67(2.99)、0.99(2.69)和0.50 Gy(2.05 Gy),对于隆突配准分别为0.14(1.80)、0.77(2.95)和0.06 Gy(1.71 Gy)。发现对于骨骼配准,最大脊髓剂量、平均食管剂量和平均肺剂量分别增加至10.93、7.92和5.69 Gy,隆突配准产生类似的值。分别有44%和22%的患者在骨骼和隆突配准中至少有一个剂量指标变化至少5 Gy(剂量指标)或体积指标变化至少5%。对GTV覆盖情况的研究表明,对于骨骼配准,V、D和D的平均(标准差)变化分别为-5.5%(13.5%)、2.5%(4.2%)和0.8%(8.9%),隆突配准结果相似。
肺不张的消退平均导致质量和密度降低,并在一部分患者队列中引起正常组织剂量指标的显著变化。